Destiny Pharma (DEST) , a clinical stage biotechnology company, has announced the publication of new microbiological data on XF-73, its leading antibacterial drug.
The paper, published in Frontiers in Cellular and Infection Microbiology, examined the efficacy of XF-73 against more than 2,500 Staphylococcus isolates. The research found that XF-73 was effective against all tested antibiotic resistance mechanisms and all 2,527 isolates.
XF-73 was also effective against 840 MRSA clinical isolates and effective against clinically significant Staphylococcus species.
These findings highlight the need for XF-73 nasal's global regulatory approval, given its broad effectiveness against various Staphylococcus isolates, including resistant strains, without observed resistance. The study underscores XF-73's potential to improve current nasal antibiotics, addressing rising Staphylococcus aureus antibiotic resistance and enhancing infection reduction strategies.
Chris Tovey, CEO of Destiny Pharma, said: "The World Health Organisation has declared antimicrobial resistance to be one of the top ten global public health threats facing humanity. These new findings underscore the transformative potential of XF-73 nasal not only to prevent post-surgical infection of a vast range of staphylococcal strains but also, critically, to be effective against all S. aureus tested antibiotic resistant strains. We look forward to sharing further details on the importance of these findings at our XF pipeline event later today."
View from Vox
There is a large addressable market for Destiny Pharma's XF-73 nasal gel, with approximately 70-90% of post-surgical infections caused by patients’ endogenous pathogens, while the majority of infections are caused by a pathogen that resides in the nose. By preventing post-surgical infections, XF-73 nasal has the potential to reduce hospitalisation stays and accelerate recovery for patients undergoing vital surgeries.
A recent European market research report further underscores the potential of XF-73, finding the nasal gel to be a highly promising alternative to the current standard treatment, mupirocin. It concluded that XF-73 has the potential to become the preferred nasal decolonisation agent for pre-surgical procedures.
Looking ahead, Dr Bill Love, Chief Scientific Officer of Destiny Pharma said “The publication data set will support the approval process for this breakthrough drug in our lead indication for the prevention of postsurgical staphylococcal infection."
Destiny Pharma’s shares jumped 17% on the news.
Follow Destiny Pharma for more News and Updates: